Analysed EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) News Sources
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
28-05-2026
yahoo.com
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
19-06-2026
yahoo.com
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
07-07-2026
yahoo.com
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
13-07-2026
yahoo.com
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High?
10-08-2026
yahoo.com
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
13-08-2026
yahoo.com
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
08-09-2026
yahoo.com
What is the current price of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?
The current price of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is $8.11.
EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) absolute price change since previous trading day?
The absolute price change of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) since the previous trading day is $0.04.
EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) percentage price change since previous trading day?
The percentage price change of EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) since the previous trading day is 0.4957%.
What is the most recent average sentiment score for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?
The most recent average sentiment score for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is 65 out of 100.
What is the most recent average sentiment for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)?
The most recent sentiment for EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ) is .
SEC-8K** Filing Available For EUPRAXIA PHARMACEUTICALS INC (EPRX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.